//

Dendreon, Corp.

Posted Mon, 09/14/2009 - 12:26 by Zefu

Dendreon, Corp.

3005 First Avenue
Seattle, WA 98121
USA
Phone: (206) 256-4545
Fax: (206) 256-0571
Email: pr@dendreon.com
Web Site: http://www.dendreon.com/

A. Company Profile

Dendreon (NASDAQ:DNDN) focuses on the development of targeted therapies for the treatment of cancer. The Company's innovative approaches include four therapeutic platforms: therapeutic vaccines, monoclonal antibodies, small molecules, and prodrugs.

B. Products

Product Pipelines
Product Indication Clinical Status
APC8024 Breast, colorectal, and ovarian cancers Phase II
Provenge Prostate cancer Phase III
Mylovenge Multiple myeloma Phase III

1. APC8024

Autologous antigen presenting cells were collected by leukapheresis and loaded with BA7072, an antigen construct consisting of recombinant sequences from both the extracellular and intracellular domains of HER2 (HER500) fused to human GM-CSF. The resulting vaccine is APC8024, an anti-HER2 vaccine.

2. Provenge

Provenge is an investigational therapeutic cancer vaccine (include dendrites) and stimulates a person's own immune system against prostate cancer cells. It was developed through Denderon's propertary antigen delivery cassette technology, a recombinant form of an antigen found in 95% of prostate cancers, prostatic acid phosphatase (PAP).

Provenge was generally well tolerated; the most common side effects, chills and fever, were mild to moderate and typically went away within one or two days.

3. Mylovenge

Mylovenge (APC8020) is an immunotherapy product consisting of autologous dendritic cells pulsed with the patient's immunoglobulin idiotype, which is a tumor-specific antigen.